Marker Therapeutics, Inc.

Tagged: TPIV200

TapImmune to Present at The MicroCap Conference

TapImmune President and CEO, Peter Hoang, to present at 2018 The Microcap Conference.

Read More

TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research

The publication of clinical data from a Phase 1 trial of TPIV200, the company’s multi-epitope T-cell vaccine targeting Folate Receptor Alpha in patients with ovarian and breast cancer will be available online today.

Read More

TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer

Triple-negative breast cancer is a difficult-to-treat condition, but one where patients may stand to benefit significantly from immunotherapies that are effective at continually fighting off disease progression long after initial cancer therapy. As a multi-peptide therapeutic vaccine, TPIV200 is designed to do just that.

Read More